CARsgen Therapeutics-B (02171): Kailimei Research Findings Presented at the 2026 ESMO Annual Meeting

Zhitong Finance APP News, CARsgen Therapeutics-B (02171) announces that the preliminary results of the clinical trial (CT041-CG4010, NCT06857786) conducted in China of Kailimei (satricabtagene autoleucel injection, product code: CT041, an autologous CAR-T cell therapy candidate targeting Claudin18.2) for consolidation therapy after adjuvant treatment in patients with Claudin18.2-positive gastric/gastroesophageal junction cancer following radical resection were presented as a poster at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on October 25, 2026 (Sunday) from 12:00-12:45 Central European Summer Time (CEST).